Mansoor Raza Mirza

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract 239: Potent synergy between CHK1/2 inhibitor ACR-368 and the ADC payload topoisomerase I inhibitor: Rationale for ADC + ACR-368 combination therapy.

  Cancer Research · 2026-04-03

• Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

  2025-11-25

• Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

  2025-11-25

• Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis

  International Journal of Gynecological Cancer · 2025-10-10 · 1 citations

• Systematic nurse-led consultations based on electronic patient-reported outcomes for women with endometrial or ovarian cancer during chemotherapy—a feasibility study

  Supportive Care in Cancer · 2025-09-17

• Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer

  The Oncologist · 2025-09-13 · 2 citations

• A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel

  Therapeutic Advances in Medical Oncology · 2025-09-01

• (ENCORE) Long-term safety and efficacy of selinexor maintenance treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

  Gynecologic Oncology · 2025-09-01

• Post hoc tipping point and multiple imputation analyses to determine the impact of early censored patients in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

  Gynecologic Oncology · 2025-09-01

• Corrigendum to “First-line treatments for advanced or recurrent endometrial cancer: Systemic literature review of clinical evidence” [Crit. Rev. Oncol./Hematol. 206 (2025) 104555]

  Critical Reviews in Oncology/Hematology · 2025-08-12

• NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer

  Gynecologic Oncology · 2025-07-01 · 1 citations

• FIRST/ENGOT-OV44: A phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC).

  Journal of Clinical Oncology · 2025-06-04 · 7 citations

• TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer.

  Journal of Clinical Oncology · 2025-05-28 · 1 citations

• Time to quality of life (QoL) improvement or deterioration in patients (pts) with primary advanced or recurrent endometrial cancer (pA/R EC) treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.

  Journal of Clinical Oncology · 2025-05-28

• Post-hoc analysis evaluating selinexor maintenance therapy in patients with <i>TP53</i> wt endometrial cancer: Progression-free survival by clinical factors in the ENGOT-EN5/GOG-3055/SIENDO study.

  Journal of Clinical Oncology · 2025-05-28

• Time to subsequent therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) receiving dostarlimab plus carboplatin-paclitaxel (DOST+CP) compared with pts receiving placebo plus CP (PBO+CP) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.

  Journal of Clinical Oncology · 2025-05-28

• Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians’ choice in advanced/recurrent endometrial carcinoma previously treated with anti–PD-(L)1 immunotherapy.

  Journal of Clinical Oncology · 2025-05-28

• Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel

  International Journal of Gynecological Cancer · 2025-05-21 · 1 citations

• Table S3 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical TrialsPreprint

  2025-05-13

• Table S8 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical TrialsPreprint

  2025-05-13